62234-36-0

Basic information

• Product Name: N-α-Z-N-β-Boc-D-2,3-diaminopropionic acid
• Synonyms: N-α-Z-N-β-Boc-D-2,3-diaminopropionic acid;N-a-Z-N-Boc-D-2,3-diaminopropionicacid;3-[[(1,1-DIMETHYLETHOXY)CARBONYL]AMINO]-N-[(PHENYLMETHOXY)CARBONYL]-D-ALANINE;N-Cbz-N'-Boc-D-2,3-diaminopropionic acid;D-N-Cbz-3-N-Boc-Amino-alanine;D-Alanine, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-N-[(phenylmethoxy)carbonyl]-;Z-D-Dap(Boc)-OH N-α-Z-N-β-Boc-D-2,3-diaMinopropionic acid;(R)-2-(((Benzyloxy)carbonyl)aMino)-3-((tert-butoxycarbonyl)aMino)propanoic acid
• CAS NO: 62234-36-0
• Molecular Formula: C16H22N2O6
• Molecular Weight: 338.36
• EINECS: 1533716-785-6
• Product Categories: Unusual Amino Acids;amino acids
• Mol File: 62234-36-0.mol

Chemical Properties

• Melting Point: 139-140 °C
• Boiling Point: 548.7 °C at 760 mmHg
• Flash Point: 285.6 °C
• Appearance: /Solid
• Density: 1.235 g/cm³
• Vapor Pressure: 7.12E-13mmHg at 25°C
• Refractive Index: 1.533
• Storage Temp.: Store at RT.
• PKA: 3.67±0.10(Predicted)
• CAS DataBase Reference: N-α-Z-N-β-Boc-D-2,3-diaminopropionic acid(CAS DataBase Reference)
• NIST Chemistry Reference: N-α-Z-N-β-Boc-D-2,3-diaminopropionic acid(62234-36-0)
• EPA Substance Registry System: N-α-Z-N-β-Boc-D-2,3-diaminopropionic acid(62234-36-0)

Safety Data

• Hazardous Substances Data: 62234-36-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-α-Z-N-β-Boc-D-2,3-diaminopropionic acid is used as an intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of novel drugs with potential applications in treating different medical conditions.
Used in Peptide Synthesis:
In the field of peptide chemistry, N-α-Z-N-β-Boc-D-2,3-diaminopropionic acid serves as a building block for the construction of complex peptide sequences. The protective Boc and Z groups facilitate the stepwise assembly of peptides, preventing unwanted side reactions and ensuring the desired product is obtained.
Used in Research and Development:
N-α-Z-N-β-Boc-D-2,3-diaminopropionic acid is also utilized in research and development for studying the structure-activity relationships of various bioactive peptides and proteins. Its unique structure allows scientists to probe the effects of specific modifications on the biological activity of these molecules.
Used in Chemical Synthesis:
N-α-Z-N-β-Boc-D-2,3-diaminopropionic acid can be employed as a starting material or a synthetic intermediate in the preparation of other organic compounds, such as chiral catalysts, ligands, and other specialty chemicals.

InChI:InChI=1/C16H22N2O6/c1-16(2,3)24-15(22)18-12(13(19)20)9-17-14(21)23-10-11-7-5-4-6-8-11/h4-8,12H,9-10H2,1-3H3,(H,17,21)(H,18,22)(H,19,20)

Upstream product

• 135841-16-6 (R)-3-benzyloxycarbonyl-5-oxo-4-oxazolidinoneacetic acid 
• 501-53-1 benzyl chloroformate 
• 4474-86-6 (R)-4-amino-2-(((benzyloxy)carbonyl)amino)-4-oxobutanoic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 62234-37-1 2-(R)-amino>-3-aminopropionic acid 
• 173259-63-7 (R)-tert-butyl-N-<(3-benzyloxycarbonyl-5-oxo-4-oxazolidinyl)-methyl>carbamate 
• 58457-98-0 methyl (2S)-2-{[(benzyloxy)carbonyl]amino}-3-[(tert-butoxycarbonyl)amino]propanoate 
• 16947-86-7 N^α-Tosyl-N^β-(tert-butpxycarbonyl)-L-α,β-diamonopropionic acid 
• 1070-19-5 N-(tert-butyloxycarbonyl) azide 
• 23632-66-8 (4S)-3-benzyloxycarbonyl-4-carboxymethyl-1,3-oxazolidin-5-one 
• 2304-96-3 N-benzyloxycarbonyl-L-asparagine 
• 126046-25-1 (S)-3-Benzyloxycarbonyl-4-<(N-tert-butoxycarbonyl)aminomethyl>-5-oxazolidinone 
• 74536-29-1 (S)-2-amino-3-((tert-butoxycarbonyl)amino)propanoic acid 
• 73371-96-7 2-<<(tert-butoxycarbonyl)oxy>imino>-2-phenylacetonitrile 

Relevant articles and documents

Elastase Inhibitor Cyclotheonellazole A: Total Synthesis and in Vivo Biological Evaluation for Acute Lung Injury

Acute lung injury/acute respiratory distress syndrome (ALI/ARDS) is one of the most common complications in COVID-19. Elastase has been recognized as an important target to prevent ALI/ARDS in the patient of COVID-19. Cyclotheonellazole A (CTL-A) is a nat

PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR

The present invention is directed to novel prodrugs of modulators of the NMDA receptor of formula I. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorders or neuropsychiatric disorders such as depression.

PYRROLOBENZODIAZEPINE DIMER PRECURSOR AND LIGAND-LINKER CONJUGATE COMPOUND THEREOF

The present invention relates to a pyrrolobenzodiazepine dimer prodrug and a ligand-linker conjugate compound thereof, a composition containing these, and therapeutic use thereof particularly as an anticancer drug. The stability of the compounds themselves and the stability thereof in plasma are excellent and the compounds are advantageous in terms of manifestation of toxicity, and thus the compounds are industrially useful in that it is possible to target proliferative diseases such as cancer, to perform a specific treatment, to maximize the drug efficacy, and to minimize the occurrence of side effects.

Synthesis of a series of ω-dimethylaminoalkyl substituted ethylenediamine ligands for use in enantioselective catalysis

The title compounds H2NCH((CH2)nNMe2)CH2NH2 L1-L4 (n = 1-4) are efficiently synthesized in enantiopure form. The commercial starting materials, l-asparagine, (S)-5-hydroxymethyl-2-pyrrolidinone, and (S)-6-(((benzyloxy)carbonyl)-amino)-2-((tert-butoxycarbonyl)amino)hexanoic acid, are elaborated in 6-9 standard steps to give L1 (18% overall), L2 (13%), L3 (36%) and L4 (38%) or the corresponding tris(hydrochloric acid) salts [H3NCH((CH2)nNHMe2)CH2NH3]3+ 3Cl-, which are preferable for long term storage. The sequences make use of isobutyl carbamate, Cbz, and Boc protecting groups and Hofmann type rearrangements; the dimethylamino groups are introduced at late stages, either via reductive dimethylations or nucleophilic displacements involving mesylates and HNMe2. L1-L4 chelate to [Co(en)2]3+ fragments to give octahedral complexes that catalyze numerous enantioselective reactions.

Sulfate Encapsulation in Supramolecular Structures from L -Asparagine-Derived 2,5-Diketopiperazine Scaffolds: Anion Binding

We report a new sulfate receptor, anchored onto 2,5-diketopiperazine units, which results in the formation of two types of supramolecules; one in which the sulfate ion guest fits snugly into extended cavities and the other in which the guest is sandwiched between layers. In each case, the anion is held by six hydrogen bonds from the host. 1H NMR spectroscopic solution studies enabled the construction of Job plots, and calculation of stoichiometry and association constants. These findings are of possible significance in drug design and for construction of combinatorial libraries.

Chemoenzymatic and chemical routes to the nonproteinaceous amino acid albizziine and its amide derivative

A two-step route for the synthesis of albizziine from Na-Boc-asparagine which proceeds in 65% overall yield is disclosed. A high-yielding, six-step route for the synthesis of its protected amido derivative gives rapid access to a key component of the complex aminopolyol natural product, zwittermicin A. Georg Thieme Verlag Stuttgart.

A new approach to the neoglycopeptides: Synthesis of urea- and carbamate-tethered N-acetyl-D-glucosamine amino acid conjugates

(Chemical Equation Presented) A novel approach to the synthesis of Fmoc-protected neoglycopeptide building blocks is described. Oxidation of N-acetyl-D-glucosamine isonitrile afforded the corresponding highly reactive glycopyranosyl isocyanate, which reacted with amino acid derivatives to furnish the corresponding urea- and carbamate-tethered Fmoc-protected N-acetyl-D-glucosamine amino acid conjugates in good yields.

ETHER DERIVATIVE

The present invention relates to an ether derivative represented by the formula (I), a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof wherein each symbol is as defined in the description, and an ether derivative represented by the formula (III), a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof wherein each symbol is as defined in the description; a pharmaceutical composition containing the ether derivative; and a package containing the pharmaceutical composition and a description of use thereof. A pharmaceutical composition of the present invention, which contains this compound of the present invention has a superior anti-inflammatory and analgesic activity and is useful as various pharmaceutical agents such as an anti-inflammatory agent, an analgesic, a therapeutic agent for inflammatory bowel disease, a therapeutic agent for pollakiuria and/or incontinentia, a therapeutic agent for asthma and the like.

NOVEL ETHYLENEDIAMINE DERIVATIVES

A compound represented by the following formula (1):Q-Q-T-N(R)-Q-N(R)-T-Q [wherein, R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may have a substituent, or the like; Q2 is a single bond or the like; Q3 represents the following group: -C(R3a)(R4a)-{C(R3b)(R4b)}m1-{C(R3c)(R4c)}m2-{C(R3d)(R4d)}m3-{C(R3e)(R4e)}m4-C(R3f)(R4f)- (in which, R3a to R4e represent hydrogen or the like); T0 represents a carbonyl group or the like; and T1 represents -COCONR- or the like]; or salt thereof, solvate thereof, or N-oxide thereof. The compound is useful as a preventive and/or therapeutic agent for cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

Synthesis of alanine and proline amino acids with amino or guanidinium substitution on the side chain

Competitive binding of peptides containing basic amino acids to disrupt or prevent the Tat-TAR interaction could result in diminished transcription as well as translation and hence constitutes an alternative way of controlling HIV replication. Therefore, we synthesized guanidinium and amino containing amino acids, based on a proline or an alanine scaffold. The introduction of the guanidinium moiety was best accomplished using 1H- pyrazole-1-carboxamidine hydrochloride, with Pmc used for its protection. The absence of racemization, maintained throughout the whole synthesis, was confirmed by chiral purity determination. These building blocks were smoothly incorporated into oligopeptides, which proved their suitability for use in a combinatorial approach for selecting TAR binding ligands. (C) 2000 Elsevier Science Ltd.